Continuous Glucose Monitoring With iCan i3 in Post-Bariatric Patients With Late Dumping Syndrome

This is a prospective, single-center, randomized, open-label clinical study evaluating the performance of a continuous glucose monitoring system (iCan i3) compared to conventional capillary glucose monitoring in post-bariatric patients diagnosed with late dumping syndrome.

Sixty participants will be randomly assigned (1:1) to either continuous glucose monitoring or capillary glucose monitoring for a period of 60 days. Data collected will include glycemic variability, hypoglycemic episodes, symptom correlation, and patient-reported outcomes such as fear of hypoglycemia (HFS-II) and quality of life (SF-36).

Continuous glucose data will be recorded every 3 minutes in the intervention group, while the control group will perform up to three capillary measurements per day based on symptoms.

Inclusion criteria

• Age 18-65 years
• History of Roux-en-Y gastric bypass ≥12 months
• Clinical diagnosis of late dumping syndrome
• Stable body weight (<5% variation in last 3 months)
• Ability to provide informed consent

Exclusion criteria

• Diagnosis of diabetes mellitus under treatment
• Use of antidiabetic medications (except acarbose)
• Pregnancy or breastfeeding
• Cognitive impairment affecting study participation
• Known hypersensitivity to CGM adhesives
• Conditions increasing risk of hypoglycemia (e.g., prolonged fasting)
• Active or prior malignancy
• Need for imaging procedures during study period